Abstract
The use of bleomycin sulfate as an antineoplastic agent is limited by its substantial pulmonary toxic effects. The exact incidence and prognosis of bleomycin-pneumonitis is unresolved. Although bleomycin pulmonary toxicity is thought to be dose-related, recent reports have emphasized severe reactions at low doses. Furthermore, severe pulmonary toxicity is suggested to be progressive, irreversible and ultimately, fatal. Clinical, roentgenographic and pathophysiologic recovery after severe bleomycin-induced pneumonitis is reported.

This publication has 2 references indexed in Scilit: